| 2.45 -0.08 (-3.16%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.11 | 1-year : | 3.64 |
| Resists | First : | 2.67 | Second : | 3.11 |
| Pivot price | 2.4  |
|||
| Supports | First : | 2.2 | Second : | 1.9 |
| MAs | MA(5) : | 2.54  |
MA(20) : | 2.33 |
| MA(100) : | 2.23 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.7 |
D(3) : | 80 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 2.81 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AYTU ] has closed below upper band by 42.3%. Bollinger Bands are 13.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.53 - 2.54 | 2.54 - 2.55 |
| Low: | 2.38 - 2.4 | 2.4 - 2.42 |
| Close: | 2.42 - 2.45 | 2.45 - 2.47 |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Tue, 23 Dec 2025
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Sat, 20 Dec 2025
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - Sahm
Thu, 18 Dec 2025
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Mon, 15 Dec 2025
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Mon, 15 Dec 2025
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com
Thu, 13 Nov 2025
Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 35.5 (%) |
| Shares Short | 457 (K) |
| Shares Short P.Month | 500 (K) |
| EPS | -2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.33 |
| Profit Margin | -20.6 % |
| Operating Margin | -10.9 % |
| Return on Assets (ttm) | 0.6 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | -16.3 % |
| Gross Profit (p.s.) | 4.22 |
| Sales Per Share | 6.25 |
| EBITDA (p.s.) | 0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.04 |
| Price to Sales | 0.39 |
| Price to Cash Flow | -18.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|